
A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.


A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.

Data from a pair of phase 3 trials detail the effects of sotagliflozin in patients with type 2 diabetes and other comorbidities, such as worsening heart failure and chronic kidney disease.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.

In honor of World Diabetes Day, we reached out to Lucia Novak, CRNP, to get her perspective on the role of nurses in the diabetes care model as "The Nurse and Diabetes" has been chosen as the official theme of this year's World Diabetes Day.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

A practicing endocrinologist offers her thoughts on a recent change by the AACE from the American Association of Clinical Endocrinologists to the American Association of Clinical Endocrinology.

An analysis of blood samples from more than 19k women offers greater insight into the relationship between premature menopause and cardiovascular disease risk in postmenopausal women.

Identifying early stages of chronic kidney disease in patients with sickle cell anemia has the potential of allowing for personalized treatment and better prognosis.

Analysis of data from the 5000-patient Look AHEAD Trial details the varying effects of changes in lean mass, fat mass, and waist circumference, respectively, on risk of heart failure and myocardial infarctions in patients with type 2 diabetes.

An analysis of data from 3 major health studies details associations between anti-inflammatory foods and lower risk of stroke and heart disease.

Investigators evaluate 35-year height and BMI trajectories for 200 countries and 65 million participants.

A recent trial found incorporating an online weight loss program to population health management strategies was linked to greater reductions in body weight.

In new data presented at ACG 2020, investigators report on the clinical characteristics and outcomes of chronic pancreatitis patients with CDI.

The Norfolk Diabetes Prevention Study is the largest type 2 diabetes prevention trial since the US Diabetes Prevention Program more than 20 years ago.

Analysis of data from the SUSTAIN program suggests adverse gastrointestinal events contributed little to superior weight loss seen with semaglutide versus other GLP-1 receptor agonists.

An extension study of the phase 3 trial indicate combination therapy with exenatide and dapagliflozin was effective 104 weeks after randomization in patients with type 2 diabetes and inadequate glycemic control despite metformin therapy.

Georgiana Dobri, MD, a neuroendocrinologist from Weill Cornell Medicine, discusses the approval of osilodrostat and management of Cushing's disease in 2020.

How good are your diagnostic skills? Test them with this month's Visual Dx quiz!

An analysis of women treated at Columbia University Irving Medical Center details outcomes in pregnant women with cardiovascular disease treated by a cardio-obstetrics care team.